Hydroxyapatite/Silver Nanoparticles Powders as Antimicrobial Agent for Bone Replacements

This paper reports a superficial morphological modification of the hydroxyapatite grains obtained by in situ deposition of Ag nanoparticles on natural origin calcium phosphate powder. Ceramic material was prepared in three stage bone treatment, including hydrolysis with a lactic acid, pre-calcination, and proper calcination. Subsequently, the Ag nanoparticles were synthesized by chemical reduction of Ag+ by sodium borohydride in a solution of polyvinylpyrrolidone and in presence of hydroxyapatite. Such-prepared materials were investigated with X-ray diffraction, Fourier-transformed infrared spectroscopy, atomic absorption spectrometry and scanning electron microscopy with energy dispersive spectroscopy. Furthermore, Ca/P molar ratio was calculated and microbiological tests were performed to investigate materials antimicrobial activity. The appearance of Ag nanoparticles located on phosphate surface was confirmed by SEM analysis, and no chemical bonding with hydroxyapatite was recorded by IR and XRD techniques. Additionally, the biological assessment revealed bactericidal effect on Escherichia coli and Staphylococcus aureus, while slightly affected on Enterococcus faecalis viability. This work is licensed under a Creative Commons Attribution 4.0 International License

Designing, developing and testing a chatbot for parents and carers of children and young people with rheumatological conditions (the IMPACT study):Protocol for a co-designed proof of concept study

Background: Paediatric Rheumatology is a term that encompasses over 80 conditions affecting different organs and systems. Children and young people with rheumatological chronic conditions are known to have high levels of mentalhealth problems and therefore are at risk of poor health outcomes. Clinical psychologists can help children and young people manage the daily difficulties of living with one of these conditions, however, there are insufficient paediatric psychologists in the United Kingdom. We urgently need to consider other ways of providing early, essential support to improve current wellbeing. One such way of doing this would be to strengthen the networks around the child or young person and the people whom they look to everyday for support, their parents/carers.Objective: The aim of this co-designed proof-of-concept study is to design, develop and test a chatbot intervention to support parents/carers of children and young people with rheumatological conditions.Methods: This study will begin by exploring the needs and views of children and young people with rheumatological conditions, siblings and parents/carers of those with rheumatological conditions, and health care professionals working in paediatric rheumatology. We will ask approximately 100 participants in focus groups where they think the gaps are in current clinical care and what ideas they have for improving upon these. Creative Experience Based Co-Design (EBCD) workshops will then decide upon top priorities to develop further, whilst informing the appearance, functionality and practical delivery of a chatbotintervention. Upon completion of a minimum viable product, approximately 100 parents/carers will user-test the chatbot intervention in an iterative sprint methodology.Results: We have full ethical approval for the study and enrolment began at the end of November 2023, with 42 currently enrolled into our focus groups. The anticipated completion of the study is April 2026. The primary outcome is to develop a product that is accessible and acceptable for parents/carers, to provide enhanced support compared to current clinical practice, with each parent/carer acting as their own control.Conclusions: This study will provide evidence on the accessibility, acceptability and usability of a chatbot intervention for parents of children and young people with rheumatological conditions. If proven useful for parents/carers, it could lead to a future efficacy trial of one of the first chatbot interventions to provide targeted and user suggested support for parents/carers of children with chronic health conditions in healthcare services. This study is unique in that it will detail the needs and wants from children, young people, siblings, parents/carers in improving support given to families living with paediatric rheumatologicalconditions, conducted across the whole of the UK in all paediatric rheumatological conditions at all stages of disease trajectory

Designing, developing and testing a chatbot for parents and carers of children and young people with rheumatological conditions (the IMPACT study): Protocol for a co-designed proof of concept study

Background: Paediatric Rheumatology is a term that encompasses over 80 conditions affecting different organs and systems. Children and young people with rheumatological chronic conditions are known to have high levels of mental health problems and therefore are at risk of poor health outcomes. Clinical psychologists can help children and young people manage the daily difficulties of living with one of these conditions, however, there are insufficient paediatric psychologists in the United Kingdom. We urgently need to consider other ways of providing early, essential support to improve current wellbeing. One such way of doing this would be to strengthen the networks around the child or young person and the people whom they look to everyday for support, their parents/carers. Objective: The aim of this co-designed proof-of-concept study is to design, develop and test a chatbot intervention to support parents/carers of children and young people with rheumatological conditions. Methods: This study will begin by exploring the needs and views of children and young people with rheumatological conditions, siblings and parents/carers of those with rheumatological conditions, and health care professionals working in paediatric rheumatology. We will ask approximately 100 participants in focus groups where they think the gaps are in current clinical care and what ideas they have for improving upon these. Creative Experience Based Co-Design (EBCD) workshops will then decide upon top priorities to develop further, whilst informing the appearance, functionality and practical delivery of a chatbot intervention. Upon completion of a minimum viable product, approximately 100 parents/carers will user-test the chatbot intervention in an iterative sprint methodology. Results: We have full ethical approval for the study and enrolment began at the end of November 2023, with 42 currently enrolled into our focus groups. The anticipated completion of the study is April 2026. The primary outcome is to develop a product that is accessible and acceptable for parents/carers, to provide enhanced support compared to current clinical practice, with each parent/carer acting as their own control. Conclusions: This study will provide evidence on the accessibility, acceptability and usability of a chatbot intervention for parents of children and young people with rheumatological conditions. If proven useful for parents/carers, it could lead to a future efficacy trial of one of the first chatbot interventions to provide targeted and user suggested support for parents/carers of children with chronic health conditions in healthcare services. This study is unique in that it will detail the needs and wants from children, young people, siblings, parents/carers in improving support given to families living with paediatric rheumatological conditions, conducted across the whole of the UK in all paediatric rheumatological conditions at all stages of disease trajectory

Synthesis and characterization of polymer-based coatings modified with bioactive ceramic and bovine serum albumin

This study involves the synthesis of hydroxyapatite and describes the preparation and characterization of polymer coatings based on poly(ethylene glycol) diacrylate and poly(ethylene glycol) and modified with bovine serum albumin and hydroxyapatite. Hydroxyapatite was obtained by wet chemical synthesis and characterized by X-ray diffraction and FTIR spectroscopy, and its Ca/P molar ratio was determined (1.69 ± 0.08). The ceramic and bovine serum albumin were used in the preparation of composite materials with the polymeric matrix. The chemical composition of coatings was characterized with FTIR spectroscopy, and their morphology was recorded with SEM imaging. Moreover, the measurements of surface roughness parameters and stereometric research were performed. The prepared coatings were subjected to in vitro studies in simulated body fluid and artificial saliva. Changes in chemical composition and morphology after immersion were examined with FTIR spectroscopy and SEM imaging. Based on the conducted research, it can be stated that applied modifiers promote the biomineralization process. The roughness analysis confirmed prepared materials were characterized by the micrometer-scale topography. The materials morphology and roughness, and the morphology of the newly formed apatite deposit, were dependent on the type of the used modifier, and the artificial fluid used in in vitro studies

Enhanced CD95 and interleukin 18 signalling accompany T cell receptor Vβ21.3+ activation in multi-inflammatory syndrome in children

Multisystem inflammatory syndrome in children is a post-infectious presentation SARS-CoV-2 associated with expansion of the T cell receptor Vβ21.3+ T-cell subgroup. Here we apply muti-single cell omics to compare the inflammatory process in children with acute respiratory COVID-19 and those presenting with non SARS-CoV-2 infections in children. Here we show that in Multi-Inflammatory Syndrome in Children (MIS-C), the natural killer cell and monocyte population demonstrate heightened CD95 (Fas) and Interleuking 18 receptor expression. Additionally, TCR Vβ21.3+ CD4+ T-cells exhibit skewed differentiation towards T helper 1, 17 and regulatory T cells, with increased expression of the co-stimulation receptors ICOS, CD28 and interleukin 18 receptor. We observe no functional evidence for NLRP3 inflammasome pathway overactivation, though MIS-C monocytes show elevated active caspase 8. This, coupled with raised IL18 mRNA expression in CD16- NK cells on single cell RNA sequencing analysis, suggests interleukin 18 and CD95 signalling may trigger activation of TCR Vβ21.3+ T-cells in MIS-C, driven by increased IL-18 production from activated monocytes and CD16- Natural Killer cells

Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity

Precision application of targeted therapies is urgently needed to improve long-term clinical outcomes for children affected by inflammatory arthritis, known as juvenile idiopathic arthritis (JIA). Progress has been hampered by our limited understanding of the cellular basis of inflammation in the target tissue of the disease, the synovial membrane. Here, we analyzed biopsies from the inflamed joints of treatment-naïve children with JIA, early in the course of their disease, using single-cell RNA sequencing, multiplexed immunofluorescence, and spatial transcriptomics to establish a cellular atlas of the JIA synovium. We identified distinct spatial tissue niches, composed of specific stromal and immune cell populations. In addition, we localized genes linked to arthritis severity and disease risk to effector cell populations, including tissue resident SPP1 + macrophages and fibrin-associated myeloid cells. Combined analyses of synovial fluid and peripheral blood from matched individuals revealed differences in cellular composition, signaling pathways, and transcriptional programs across these distinct anatomical compartments. Furthermore, our analysis revealed several pathogenic cell populations that are shared with adult-onset inflammatory arthritis, as well as age-associated differences in tissue vascularity, prominence of innate immunity, and enrichment of TGF-β-responsive stromal subsets that up-regulate expression of disease risk-associated genes. Overall, our findings demonstrate the need for age-specific analyses of synovial tissue pathology to guide targeted treatment strategies in JIA. </p

Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity

Precision application of targeted therapies is urgently needed to improve long-term clinical outcomes for children affected by inflammatory arthritis, known as juvenile idiopathic arthritis (JIA). Progress has been hampered by our limited understanding of the cellular basis of inflammation in the target tissue of the disease, the synovial membrane. Here, we analyzed biopsies from the inflamed joints of treatment-naïve children with JIA, early in the course of their disease, using single-cell RNA sequencing, multiplexed immunofluorescence, and spatial transcriptomics to establish a cellular atlas of the JIA synovium. We identified distinct spatial tissue niches, composed of specific stromal and immune cell populations. In addition, we localized genes linked to arthritis severity and disease risk to effector cell populations, including tissue resident SPP1+ macrophages and fibrin-associated myeloid cells. Combined analyses of synovial fluid and peripheral blood from matched individuals revealed differences in cellular composition, signaling pathways, and transcriptional programs across these distinct anatomical compartments. Furthermore, our analysis revealed several pathogenic cell populations that are shared with adult-onset inflammatory arthritis, as well as age-associated differences in tissue vascularity, prominence of innate immunity, and enrichment of TGF-β–responsive stromal subsets that up-regulate expression of disease risk–associated genes. Overall, our findings demonstrate the need for age-specific analyses of synovial tissue pathology to guide targeted treatment strategies in JIA

Research for new sunscreen group of cinnamic acid derivatives

Celem pracy była ocena, właściwości fotoochronnych oraz bezpieczeństwa stosowania (R, S-2-[(trans)-cynamoilo]-1-fenyloetanolu), pochodnej kwasu cynamonowego.W pierwszym etapie badań określono zdolność absorbowania promieniowania ultrafioletowego w zakresie UVA i UVB. W następnym etapie przeprowadzono badania cytotoksyczności z wykorzystaniem czterech linii komórkowych: fibroblastów skórnych, astrocytów mysich, neuroblastomy ludzkiej oraz komórek hepatocytów wątrobowych. Otrzymane rezultaty jednoznacznie potwierdziły bezpieczeństwo stosowania badanej pochodnej kwasu cynamonowego względem komórek prawidłowych skóry ludzkiej, jak również astrocytów. Ponadto wykluczyły działanie hepato- i neurotoksyczne. Otrzymane wyniki dowiodły, że (R, S-2-[(trans)-cynamoilo]-1-fenyloetanol) może stanowić nowy potencjalny filtr UV.The aim of the study was to assess whether a compound (R, S-2-[(trans)-cynamoil]-1-phenylethanol), a derivative of cinnamic acid, meets the criteria set for safe sunscreen filters.In the initial stage of the study the the ability to absorb ultraviolet radiation in the UVA and UVB range. Cytotoxicity assays were performed using four cell lines: the dermal fibroblasts cell line, the mouse astrocytes cell line, the human neuroblastoma cell line, the liver hepatocyte line.The obtained results clearly confirm the safety of the compound (R, S-2-[(trans)-cynamoil]-1-phenylethanol) to normal cells of human skin, as well as to astrocytes. In addition, any hepato- and neurotoxic activity was excluded.The results prove that the (R, S-2 - [(trans) -cynamoil] -1-phenylethanol) offers a new alternative to commercially available UV filters